Gastrointestinal Cancers Symposium
Gastrointestinal Cancers Symposium
February 04, 2013
1 min read
Save

Combination therapy extends survival among patients with advanced pancreatic cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The addition of nab-paclitaxel to gemcitabine significantly improved survival in treatment-naïve patients with metastatic pancreatic cancer, according to results of the phase 3 MPACT study presented at the Gastrointestinal Cancers Symposium.

In a previous phase 1/2 study, nan-paclitaxel (Abraxane, Celgene) plus gemcitabine (Gemzar, Eli Lilly) showed promising activity in patients with advanced pancreatic cancer.

In the phase 3 study, researchers randomly assigned 861 patients to nab-paclitaxel plus gemcitabine (n=431) or gemcitabine alone (n=430). Patients in the combination therapy arm received 125 mg/m² of nab-paclitaxel followed by gemcitabine 1,000 mg/m² on days 1, 8 and 15 every 4 weeks.

Daniel D. Von Hoff, MD, FACP, director of the Translational Genomics Research Institute, and colleagues treated patients until disease progression.

The median age of patients was 63 years, and baseline characteristics were balanced between the two arms, researchers said.

OS served as the primary endpoint.

Patients assigned to the combination regimen experienced a median OS of 8.5 months, compared with 6.7 months for patients assigned to gemcitabine alone (HR=0.72; 95% CI, 0.617-0.835), study results showed.

The combination therapy was associated with higher rates of 1-year survival (35% vs. 22%; P=.0002) and 2-year survival (9% vs. 4%; P=.02).

Median PFS was 5.5 months among patients assigned to the combination regimen compared with 3.7 months for those assigned to gemcitabine alone (HR=0.69; 95% CI, 0.581-0.821). The rate of 1-year PFS also was higher among the combination arm (16% vs.9%; P=.03).

The combination therapy also significantly increased median time to treatment failure (5.1 months vs. 3.6 months; HR=0.70; 95% CI, 0.604–0.803) and overall response rate (23% vs. 7%; RR=3.19; 2.178-4.662), according to study results.

Patients assigned to the combination regimen experienced higher rates of neutropenia (38% vs. 27%), fatigue (17% vs. 7%), peripheral neuropathy (17% vs. 1%) and febrile neutropenia (3% vs. 1%).

For more information:

Von Hoff DD. Abstract #LBA148. Presented at: Gastrointestinal Cancers Symposium; Jan. 24-26, 2013; San Francisco.

Disclosure: Von Hoff reports research funding from Celgene.